Boehringer Ingelheim inks 'Singapore's largest biotech deal,' promising $1B each for a suite of anti-fibrotic IL-11 drugs

The deeper Boehringer Ingelheim looks into Asian biotech, the more gems it seems to find. Having picked up new fibrotic diseases drugs left and right, the German legacy pharma is bagging a slate of experimental therapies hitting an oft-overlooked cytokine in what’s being billed as “Singapore’s largest biotech deal.”